F-1: Kazia Therapeutics Files F-1 for Resale of 10.7M ADSs

Kazia Therapeutics Limited filed an F-1 registration statement for the resale of up to 10,700,211 American Depositary Shares by selling shareholders, following recent private placements and warrant exercises.

Summary

• The company filed an F-1 registration statement for the resale of up to 10,700,211 American Depositary Shares (ADSs) by selling shareholders, with each ADS representing 500 ordinary shares.
• The total number of ordinary shares underlying the ADSs for resale is 5,350,105,500, comprising shares from a private placement, pre-funded warrants, and placement agent warrants.
• The company will not receive any proceeds from the sale of these Offered ADSs by the Selling Shareholders.
• Potential proceeds from the cash exercise of Placement Agent Warrants could be approximately $5.25 million, and nominal proceeds (approximately $93.85) from Pre-Funded Warrants, if exercised for cash.
• Kazia Therapeutics is an oncology-focused biotechnology company developing paxalisib for glioblastoma and other brain cancers, and EVT801 as a selective inhibitor of vascular endothelial growth factor receptor 3.
• The company recently regained compliance with Nasdaq Listing Rule 5550(b)(1) (minimum $2.5 million stockholders' equity) as of December 18, 2025, leading to the cancellation of a scheduled delisting hearing.
• Net proceeds of approximately $46.5 million from a private placement on December 2, 2025, are expected to extend the company's cash runway into the second half of 2028.

Sentiment

Score: 7

Explanation: The filing indicates a positive financial development with a significant capital raise and regaining Nasdaq compliance, extending the cash runway. However, the company still faces inherent risks associated with drug development, market volatility, and the fact that the current offering is a resale by existing shareholders, not a direct capital injection for the company (beyond potential warrant exercises). The company's history of accumulated losses also tempers the overall sentiment.

Positives

• Regained compliance with Nasdaq listing rules, specifically the $2.5 million minimum stockholders' equity requirement, leading to the cancellation of a delisting hearing.
• A recent private placement generated approximately $46.5 million in net proceeds, significantly bolstering the company's financial position.
• The company's cash runway is now expected to extend into the second half of 2028, providing stability for ongoing operations and development programs.
• The company has a diversified portfolio of oncology development candidates, including lead candidate paxalisib and second asset EVT801.

Negatives

• The company will not receive any proceeds from the sale of the 10,700,211 ADSs being offered for resale by the Selling Shareholders.
• The company reported accumulated losses of ($89,255,639) and negative total equity of ($5,747,268) as of June 30, 2025, on an actual basis, prior to the recent capital raise.
• The market price of the ADSs has been and is likely to continue to be highly volatile.
• If the ADS market price falls below $5.00 per share, shareholders will be unable to use them as collateral for margin accounts, potentially depressing demand and increasing volatility.
• The company has not declared or paid any cash dividends since its inception and does not intend to do so for the foreseeable future, meaning investment return depends solely on share price appreciation.

Risks

• The market price of the ADSs has been and will likely continue to be volatile, influenced by factors such as clinical trial results, competitor innovations, and changes in financial estimates.
• Adverse economic changes in Australia, the U.S., EU, or globally could materially and adversely affect the company's business or results of operations.
• Failure to meet Nasdaq's continued listing requirements, such as minimum bid price or market value of listed securities, could result in delisting of the ADSs.
• Raising additional capital in the future may cause dilution to existing shareholders, restrict operations, or require the company to relinquish valuable intellectual property rights.
• Future sales or issuances of ADSs in the public markets, or the perception of such sales, could depress the trading price of the ADSs.
• Holders of ADSs are reliant on the Depositary to exercise voting rights and receive distributions, which may lead to delays or non-receipt of certain distributions.
• The company was a Passive Foreign Investment Company (PFIC) for the 2023 taxable year, which can have adverse U.S. federal income tax consequences for U.S. holders unless specific elections are made, and PFIC status for future years is uncertain.
• Acquisitions of securities in Australian companies by foreign persons may be subject to review and approval by the Australian Federal Treasurer under Foreign Takeovers Laws, potentially leading to divestiture orders or penalties.
• Indemnification for liabilities arising under the Securities Act for directors and officers is considered against public policy by the SEC and is therefore unenforceable.

Future Outlook

The company expects the net proceeds from the recent private placement, combined with existing cash and cash equivalents, to extend its cash runway into the second half of 2028. Any proceeds received from the exercise of Placement Agent Warrants or Pre-Funded Warrants for cash will be used for general corporate purposes, including working capital, expenses related to research, clinical development, commercial efforts, and general and administrative expenses. The company is also actively exploring possible acquisition candidates for new therapeutic candidates.

Management Comments

• "We expect the net proceeds from the Private Placement, combined with the existing cash and cash equivalents, will extend our cash runway into the second half of 2028."

Industry Context

The company operates in the highly competitive and capital-intensive oncology-focused biotechnology sector, developing therapies for challenging conditions like glioblastoma and advanced breast cancer (paxalisib) and targeting vascular endothelial growth factor receptor 3 (EVT801). The recent capital raise and extended cash runway are crucial for continued drug development in this industry, which is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Regaining Nasdaq compliance is also important for maintaining investor confidence and access to public markets, a common challenge for smaller biotech firms.

Comparison to Industry Standards

• The company's lead candidate, paxalisib, targets glioblastoma, a high-unmet-need area in oncology, aligning with a common strategy for biotech companies to focus on severe diseases with limited treatment options.
• The cash runway extension into the second half of 2028 (approximately 2.5 years from the filing date) is a favorable position for a clinical-stage biotechnology company, often exceeding the typical 12-18 month cash runway seen in many smaller biotech peers.
• Successfully regaining Nasdaq compliance by meeting the $2.5 million minimum stockholders' equity requirement, after previously falling below the $35 million MVLS requirement, demonstrates effective financial management to maintain public listing, which is critical for small-cap biotech companies to access capital and maintain liquidity, a challenge many in the sector face.

Corporate Governance

Legal Proceedings

• There are no pending or, to the knowledge of the company, threatened actions, suits, inquiries, notices of violation, proceedings, or investigations against the company or its subsidiaries that would adversely affect the legality, validity, or enforceability of the Transaction Documents or the Securities, or that could reasonably be expected to result in a Material Adverse Effect.

Related Party Transactions

• Alumni Capital LP has been involved in multiple transactions, including the ELOC Purchase Agreement, January 2025 Purchase Agreement, and participation in the August 2025 Private Placement, and exercised the Alumni Warrant.
• Konik Capital Partners LLC, a division of T.R. Winston & Company, served as the placement agent for the December 2025 Private Placement and received Placement Agent Warrants, which were subsequently transferred to several individuals and entities.
• Maxim Group LLC acted as the placement agent for the January 2025 offering and received placement agent warrants.
• H.C. Wainwright & Co., LLC acted as the placement agent for the November 2023 offering and received placement agent warrants.
• Except as disclosed in the SEC Reports, no officers, directors, or employees are party to any material transaction with the company (other than for services) exceeding $120,000.

Stakeholder Impact

• Shareholders: Existing shareholders face potential dilution from the exercise of warrants and future capital raises. The resale of ADSs by selling shareholders could create downward pressure on the stock price. However, the extended cash runway and regained Nasdaq compliance provide stability.
• Employees: Continued operations due to the extended cash runway ensure job security and stability.
• Customers/Patients: Continued drug development efforts for paxalisib and EVT801 could lead to new therapeutic options.
• Creditors: Improved financial stability and an extended cash runway reduce immediate solvency concerns, enhancing the company's ability to meet its obligations.
• Regulatory Authorities: The company has demonstrated compliance with Nasdaq listing rules, maintaining its standing with regulatory bodies.

Next Steps

• Selling shareholders may offer or resell the 10,700,211 Offered ADSs from time to time.
• The company will use proceeds from any exercise of Placement Agent Warrants or Pre-Funded Warrants for general corporate purposes, including working capital, research, clinical development, commercial efforts, and general and administrative expenses.
• The company is exploring possible acquisition candidates for new therapeutic candidates.
• The company will continue to maintain the listing of its ADSs on the Nasdaq Capital Market.
• The company will file a post-effective amendment to the registration statement to include any financial statements required by Item 8.A of Form 20-F at the start of any delayed offering or throughout a continuous offering.

Key Dates

Recommendation

The company has successfully addressed immediate financial and listing concerns through a significant private placement and regaining Nasdaq compliance, extending its cash runway into the second half of 2028. This provides a period of stability for its oncology drug development programs (paxalisib and EVT801). However, the current filing is primarily for the resale of shares by existing investors, meaning no new capital is directly flowing to the company from this specific offering (beyond potential warrant exercises). The inherent risks of clinical-stage biotechnology, including trial outcomes and market volatility, remain significant. Given the recent positive financial developments and ongoing R&D, a 'hold' recommendation is appropriate for investors to monitor the progress of its pipeline and further financial developments without adding new capital at this stage, especially since the company has a history of accumulated losses and does not intend to pay dividends.

Keywords

Kazia Therapeutics, Biotechnology, Oncology, Paxalisib, Glioblastoma, EVT801, VEGFR3 inhibitor, SEC Filing, F-1 Registration, ADSs, American Depositary Shares, Private Placement, Warrants, Nasdaq Listing, Capital Raise, Drug Development, Clinical Trials, Risk Factors, Foreign Private Issuer, PFIC